Submission of Press Release on Q2 FY27 financial results

November 4, 2026 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Phiroz Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (E), 25th floor, Dalal Street, MUMBAI -400 051 MUMBAI -400 001 Company Code No. AUROPHARMA Company Code No. 524804 Dear Sir / Madam, Sub: Press Release on Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2026. We enclose a copy of the Press Release on Unaudited Financial Results of the Company for the second quarter ended September 30, 2026 Please take the information on record. Yours faithfully, For AUROBINDO PHARMA LIMITED B. Adi Reddy Company Secretary Enclosures: as above. Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana, India Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com AUROBINDO PHARMA LIMITED Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Hyderabad – 500 032. Telangana, India Press Release Hyderabad, India, November 4th, 2026: Aurobindo Pharma Limited (BSE: 524804 and NSE: AUROPHARMA) ("Aurobindo") today announced its consolidated financial results for the quarter ended September 30, 2026. Aurobindo Pharma Limited Q2FY27 Amount (INR Cr) Q2FY27 Q2FY26 Q1FY27 Change YoY Change QoQ Revenue from Operations 10,263 8,286 23.9% 9,150 12.2% EBITDA 2,156 1,678 28.5% 1,881 14.6% (Before Forex and Other Income) EBITDA Margin (%) 21.0% 20.3% 75 bps 20.6% 45 bps PBT before share of P/L of JV 1,691 1,274 32.7% 1,517 11.5% Net Profit for the period 1,124 848 32.5% 1,032 8.9% Key High lights of Q2FY27 • Highest ever quarterly Revenue from Operations of INR 10,263 Cr, reporting an increase of 24% YoY, driven by growth across businesses • US revenue increased by 25% YoY to INR 4,555 Cr (USD 477 million) • Europe revenue increased by 27% YoY to INR 3,161 Cr (EUR 288 million) • Growth Markets revenue increased by 16% YoY to INR 1,026 Cr (USD 107 million) • ARV revenue for the quarter stood at INR 359 Cr (USD 38 million) • Received final approval for 12 products from USFDA • R&D expenditure for the quarter stood at INR 376 Cr against INR 344 Cr in the previous quarter • Net Profit for the quarter stood at INR 1,124 Cr • Generated strong free cash flows of USD 146 million during the quarter after accounting for strategic capex investments • Strong net cash position (including investments) of USD 189 million as on 30-Sep-26 • Basic and Diluted EPS stood at INR 19.57 per share • Declared an interim dividend of ₹ 7.0 per share AUROBINDO PHARMA LIMITED Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Hyderabad – 500 032. Telangana, India Commenting on the Company’s performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: “We are pleased to deliver a strong performance in Q2, reflecting the strength of our business fundamentals, sustained execution and the resilience of our diversified product portfolio. Our growth is supported by healthy organic momentum across our key businesses and the successful integration of inorganic opportunities, further strengthening our capabilities and positioning us for the future. As we advance our strategic priorities, we remain focused on sustainable growth, financial discipline and creating long-term value for our stakeholders, while continuing to expand access to quality and affordable healthcare worldwide.” Operati onal Performance (Consolidated) ₹ Cr Q2FY27 Q2FY26 YoY (%) Q1FY27 QoQ (%) USA 4,555 3,638 25.2% 3,770 20.8% Europe 3,161 2,480 27.5% 2,937 7.6% Growth Markets 1,026 882 16.3% 1,063 -3.5% ARV 359 325 10.2% 330 8.7% Total Formulations 9,102 7,325 24.2% 8,101 12.4% Beta-lactam 858 687 24.8% 800 7.3% Non Beta-lactam 304 273 11.3% 250 21.7% Total API 1,162 961 20.9% 1,049 10.7% Revenue from Operations 10,263 8,286 23.9% 9,150 12.2% Q2FY27 : Consolidated Revenue Breakup - Geography & Business Wise Q2FY27 Domestic, 8% API, 11% US, 44% ARV, 3% Growth Markets, 10% Europe, 31% International, AUROBINDO PHARMA LIMITED Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Hyderabad – 500 032. Telangana, India FoQr2mFuYl2a7ti:o Bnsu siness Wise Performance Formulations revenue increased by 24% YoY to INR 9,102 Cr. US Formulations • US revenue increased by 25% YoY to INR 4,555 Cr primarily driven by successful integration, base business growth and new launches • As on 30-Sep-26, on a cumulative basis, the company filed 900 ANDAs with USFDA and received 747 final approvals and 35 tentative approvals • Launched 10 products in the US market (including gAdvair and ADQUEYTM our first NCE) Europe Formulations • Europe revenue increased by 27% YoY to INR 3,161 Cr, driven by robust performance across all key markets; and accounted for 31% of consolidated revenue • In euro terms, revenue increased by 18% YoY to EUR 288 million Growth Markets Formulations • Growth Markets formulations revenue increased by 16% YoY to INR 1,026 Cr, driven by strong performance across key markets; and accounted for 10% of consolidated revenue • In USD terms, revenue increased by 6% YoY to USD 107 million ARV Formulations • ARV business revenue remained broadly stable at INR 359 Cr with QoQ variation driven by tender opportunities, accounting for 3% of consolidated revenue • In USD terms, revenue increased by 7% QoQ to USD 38 million Active Pharmaceutical Ingredients (API) • API revenues increased 21% YoY to INR 1,162 Cr, driven by favorable business mix and contributed 11% of consolidated revenue • In USD terms, revenue increased by 11% YoY to USD 122 million AUROBINDO PHARMA LIMITED Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Hyderabad – 500 032. Telangana, India Q2FY27: Final USFDA Approvals Received Aurobindo Pharma Limited # Product Strength Therapy Area Sacubitril and Valsartan Tablets (FTF) 24 mg/26 mg, 49 mg/51 mg 1 CARDIO VASCULAR and 97 mg/103 mg Etodolac Tablets USP 400 mg and 500 mg NONSTEROIDAL ANTI- INFLAMMATORY DRUG (NSAID) Bupropion Hydrochloride Extended-Release 150 mg and 300 mg 3 CENTRAL NERVOUS SYSTEM Tablets USP Vancomycin Hydrochloride for Oral Solution 25 mg/mL and 50 mg/mL 4 ANTI-INFECTIVE Triamcinolone Acetonide Nasal Spray USP (OTC) 55 mcg per spray 5 RESPIRATORY DRUGS Metronidazole Vaginal Gel 0.75% 6 ANTI-INFECTIVE Adapalene and Benzoyl Peroxide Topical Gel 0.3%/2.5% 7 ANTI-INFECTIVE Cyclosporine Capsules USP (Modified) (Soft 25 mg, 50 mg and 100 mg 8 IMMUNOSUPPRESSIVE AGENTS Gelatin Capsules) Isotretinoin Capsules USP 20 mg, 30 mg and 40 mg 9 ANTI-INFECTIVE Brivaracetam Oral Solution 10 mg/ mL 10 CENTRAL NERVOUS SYSTEM Beclomethasone Dipropionate HFA, Inhalation 40 mcg and 80 mcg 11 CORTICOSTEROID Aerosol Eslicarbazepine Acetate Tablets^^ 200 mg, 400 mg, 600 mg and 12 CENTRAL NERVOUS SYSTEM 800 mg ^^ Received Tentative approval earlier; now received Final approval Q2FY27: Earnings Call Details The company will host earnings call at 8.30 AM IST on 05-Nov-26, to discuss the performance and answer any questions from participants. To join the call through Zoom, please pre-register using the link: https://bit.ly/4yDZFGo AUROBINDO PHARMA LIMITED Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Hyderabad – 500 032. Telangana, India About Aurobindo Pharma Limited Au robindo Pharma Limited (www.aurobindo.com) (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commer [Showing first 8,000 characters — download PDF for full document]